Modelling study applying SELECT trial risk factor changes to 21,720 survey participants with BMI 27 or more and SCORE2 risk 7.5% or more without CVD: emulated GLP-1RA therapy lowered projected 10-year CVD incidence from 13.82% to 10.83%.
RCTn = 21,720
Schrage et al. Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population